Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Harvard Business School

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,916,131

« Back to Dashboard

Which drugs does patent 8,916,131 protect, and when does it expire?

Patent 8,916,131 protects VIZAMYL and is included in one NDA.

This patent has nineteen patent family members in eighteen countries.

Summary for Patent: 8,916,131

Title:Radiopharmaceutical composition
Abstract: The present invention relates to radiopharmaceuticals and in particular to a radiopharmaceutical composition comprising a compound of Formula (I): and polysorbate as an excipient. The radiopharmaceutical composition of the invention reduces problems encountered with prior art compositions comprising the same class of compounds. Also provided by the invention is a method for the preparation of the radiopharmaceutical composition of the invention as well as particular uses of the radiopharmaceutical composition. ##STR00001##
Inventor(s): Roed; Line (Oslo, NO), Peterson; Sarah Elizabeth (Amersham, GB)
Assignee: GE Healthcare Limited (Buckinghamshire, GB)
Application Number:12/673,602
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
Ge HealthcareVIZAMYLflutemetamol f-18INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,916,131

PCT Information
PCT FiledAugust 28, 2008PCT Application Number:PCT/EP2008/061275
PCT Publication Date:March 05, 2009PCT Publication Number: WO2009/027452

International Patent Family for Patent: 8,916,131

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2010101935► Subscribe
Portugal2182988► Subscribe
New Zealand583616► Subscribe
Norway2015006► Subscribe
Mexico2010002196► Subscribe
South Korea101571572► Subscribe
South Korea20100055440► Subscribe
Japan5367708► Subscribe
Japan2010536931► Subscribe
Israel203316► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Chinese Patent Office
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: